Drug Approval | January 19, 2024
Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron developed to reduce the number of infusions
Subscribe To Our Newsletter & Stay Updated
